IP Library Granted Patent US 9,744,252
Granted Patent B2
US 9,744,252 · App. 15/003,368 · Granted Aug 29, 2017

Compounds for binding to the platelet specific glycoprotein IIb/IIIa and their use for imaging of thrombi

Inventors: Markus Berger (Berlin, DE); Martin Kruger (Berlin, DE); Jessica Lohrke (Berlin, DE); Michael Reinhardt (Berlin, DE); Holger Siebeneicher (Berlin, DE)
Assignee: PIRAMAL IMAGING SA
A61K51/088A61J1/06A61K49/0433C07D211/60C07D401/04C07D401/06C07D401/14C07K5/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,744,252
App. No.
15/003,368
Granted
Aug 29, 2017
Kind
B2
Abstract

The present invention relates to novel fluorine containing compounds, methods for their preparation, the intermediates of the synthesis, their use as diagnostic agents, especially for imaging of thrombi. The invention relates to positron emission tomography (PET) agents and associated precursor reagents, and methods for producing such radiolaveled agents for imaging of thrombi in a mammalian body. More particularly, the invention relates to small nonpeptide, high-affinity, specific-binding glycoprotein IIb/IIIa antagonists for imaging of thrombi.

Claims (241)

1. Compounds of Formula I:

wherein

R 1 is hydrogen or an amine-protecting group;

R 2 is hydrogen or a carboxyl-protecting group;

wherein at least one of R 1 and R 2 is not H;

R 3 is selected from the group consisting of H, F, CF 3 , COR 9 , COOR 10 , SOR 10 , SO 2 R 10 , CN and NO 2 ;

R 4 is selected from the group consisting of OH, Halogen, —NO 2 , —N + (Me) 3 (W − ), —I + R 11 (W − )—O(CH 2 ) n -LG, —(OCH 2 CH 2 ) m -LG, Q, —OCH 2 -Q; —CH 2 —CH 2 -Q, —CH═CH-Q and —C≡C-Q;

X is selected from CH or N;

LG is a leaving group;

R 9 is hydrogen or (C 1 -C 6 )alkyl;

R 10 is (C 1 -C 6 )alkyl;

R 11 is selected from the group consisting of phenyl, (4-methyl)phenyl, (4-methoxy)phenyl, 2-furanyl and 2-thienyl;

W − is selected from the group comprising CF 3 (S(O) 2 O − , iodide anion, bromide anion and CF 3 C(O)O − ;

Q is a group

wherein * indicates the atom of connection of Q;

R 5 is selected from the group consisting of H, CF 3 , COR 9 , COOR 10 , SOR 10 , SO 2 R 10 , CN and NO 2 ;

R 6 is selected from the group consisting of OH, Halogen, —NO 2 , —N + (Me) 3 (W − ), —I + R 11 (W 31 ), —O(CH 2 ) n -LG and —(OCH 2 CH 2 ) m -LG;

n is 1-3;

and m is 2-3;

with the proviso that if R 4 has the meaning of Halogen, —NO 2 , —N + (Me) 3 (W − ) or —I + R 11 (W − ), R 3 has the meaning of CF 3 , COR 9 , COOR 10 , SOR 10 , SO 2 R 10 , CN or NO 2 and

with the proviso that if R 6 has the meaning of Halogen, —NO 2 , —N + (Me) 3 (W − ) or —I + R 11 (W − ), R 5 has the meaning of CF 3 , COR 9 , COOR 10 , SOR 10 , SO 2 R 10 , CN or NO 2 ;

including E and Z-isomers and diastereomers, mixtures thereof, and any pharmaceutically acceptable salt or complex thereof.

2. Compounds according to claim 1 , wherein

R 1 is hydrogen or an amine-protecting group;

R 2 is hydrogen or a carboxyl-protecting group;

wherein at least one of R 1 and R 2 is not H;

R 3 is H, F, CF 3 , CN or NO 2 ;

R 4 is OH, Halogen, —N + (Me) 3 (W − ), —O(CH 2 ) n -LG, —(OCH 2 CH 2 ) m -LG, Q, —OCH 2 -Q; —CH 2 —CH 2 -Q, —CH═CH-Q or —C≡C-Q;

X is CH or N;

LG is a leaving group;

W − is CF 3 (S(O) 2 O − , a bromide anion or CF 3 C(O)O − ;

Q is a group

wherein * indicates the atom of connection of Q;

R 5 is H, CF 3 , CN or NO 2 ;

R 6 is OH, Halogen, —N + (Me) 3 (W − ), —O(CH 2 ) n -LG and or —(OCH 2 CH 2 ) m -LG;

n is 1-3;

and m is 2-3;

with the proviso that if R 4 has the meaning of Halogen or —N + (Me) 3 (W − ), R 3 has the meaning of CF 3 , CN or NO 2 and

with the proviso that if R 6 has the meaning of Halogen or —N + (Me) 3 (W − ), R 5 has the meaning of CF 3 , CN or NO 2 ;

including E and Z-isomers and diastereomers and mixtures thereof.

3. Compounds according to claim 1 , wherein

R 1 is hydrogen or an amine-protecting group selected from the group consisting of tert-butyloxycarbonyl (BOC), carbobenzyloxy (Cbz) and 9-fluorenylmethyloxycarbonyl (FMOC);

R 2 is hydrogen or a carboxyl-protecting group selected from the group consisting of methyl, ethyl, propyl, tert-butyl, benzyl and p-methoxybenzyl;

wherein at least one of R 1 and R 2 is not H;

R 3 is H, F, CF 3 , CN or NO 2 ;

R 4 is OH, Halogen, —N + (Me) 3 (W − ), —O(CH 2 ) n -LG, —(OCH 2 CH 2 ) m -LG, Q, —OCH 2 -Q; —CH 2 —CH 2 -Q, —CH═CH-Q or —C≡C-Q;

X is CH or N;

LG is a leaving group selected from the group comprising methylsulfonyloxy and (4-methylphenyl) sulfonyloxy;

W − is CF 3 (S(O) 2 O − , a bromide anion or CF 3 C(O)O − ;

Q is a group

wherein * indicates the atom of connection of Q;

R 5 is H, CF 3 , CN or NO 2 ;

R 6 is OH, Halogen, —N + (Me) 3 (W − ), —O(CH 2 ) n -LG or —(OCH 2 CH 2 ) m -LG;

n is 1-3;

and m is 2-3;

with the proviso that if R 4 has the meaning of Halogen or —N + (Me) 3 (W − ), R 3 has the meaning of CF 3 , CN or NO 2 and

with the proviso that if R 6 has the meaning of Halogen or —N + (Me) 3 (W — ), R 5 has the meaning of CF 3 , CN or NO 2 ;

including E and Z-isomers and diastereomers and mixtures thereof.

4. Compounds according to claim 1 , wherein

R 1 is tert-butyloxycarbonyl (BOC);

R 2 is methyl or tert-butyl;

wherein at least one of R 1 and R 2 is not H;

R 3 is H;

R 4 is —O(CH 2 ) n -LG;

X is N;

LG is methylsulfonyloxy or (4-methylphenyl)sulfonyloxy;

W − is CF 3 (S(O) 2 O − , a bromide anion or CF 3 C(O)O − ;

Q is a group

wherein * indicates the atom of connection of Q;

R 5 is H, CF 3 , CN or NO 2 ;

R 6 is OH, Halogen, —N + (Me) 3 (W − ), —O(CH 2 ) n -LG or —(OCH 2 CH 2 ) m -LG;

n is 1-3;

and m is 2-3;

with the proviso that if R 6 has the meaning of Halogen or —N + (Me) 3 (W − ), R 5 has the meaning of CF 3 , CN or NO 2 ;

including E and Z-isomers and diastereomers and mixtures thereof.

5. Compounds of Formula I according to claim 1 , selected from:

tert-butyl 4-{3-[(3R)-3-({(1S)-3-methoxy-1-[3-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)-phenyl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-({3-methoxy-1-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-({(1S)-3-tert-butoxy-1-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-({(1S)-3-methoxy-1-[5-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylat,

tert-butyl 4-{3-[(3R)-3-({(1S)-3-tert-butoxy-1-[5-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-{[3-methoxy-1-{5-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)-phenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}-ethoxy)phenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate;

tert-butyl 4-{3-[(3R)-3-({1-[5-(4-chloro-3-cyanophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl-4-{3-[(3R)-3-{[(1S)-1-{5-[(3-bromo-4-cyanobenzyl)oxy]pyridin-3-yl}-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-{[3-methoxy-1-{5-[3-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)-phenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-{[3-methoxy-1-{5-[2-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)-phenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-({1-[5-(4-chloro-3-nitrophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-({1-[5-fluoro-4′-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)biphenyl-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[3-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{2-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{2-[3-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-[3-((3R)-3-{[1-(4-hydroxyphenyl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl)-3-oxopropyl]piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-({(1S)-1-[3-hydroxyphenyl]-3-methoxy-3-oxopropyl}carbamoyl)-piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-({(1S)-1-[5-(hydroxy)pyridin-3-yl]-3-methoxy-3-oxopropyl}-carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-({1-[5-(3-hydroxyphenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}-carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-({1-[5-(4-hydroxyphenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}-carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-({1-[5-(2-hydroxyphenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}-carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-{[(1-(5-fluoro-4′-hydroxybiphenyl-3-yl)-3-methoxy-3-oxopropyl]-carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(4-hydroxyphenyl)-3-oxopropyl]-carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-hydroxypyridin-3-yl)-3-oxopropyl]-carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-({(1S)-3-tert-butoxy-1-[5-(4-hydroxyphenyl)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-(3-{(3R)-3-[(3-tert-butoxy-1-{5-[(4-hydroxyphenyl)ethynyl]pyridin-3-yl}-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[(3-hydroxyphenyl)ethynyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-(3-{(3R)-3-[(3-tert-butoxy-1-{5-[2-(4-hydroxyphenyl)ethyl]pyridin-3-yl}-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate, and

tert-butyl 4-(3-{(3R)-3-[(3-tert-butoxy-1-{5-[2-(3-hydroxyphenyl)ethyl]pyridin-3-yl}-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate.

6. A kit comprising a sealed vial containing a predetermined quantity of a compound selected from the compounds of Formula I according to claim 1 , stereoisomers thereof and their mixtures, suitable salts of inorganic or organic bases and acids thereof, and hydrates, complexes, esters, amides, and solvates thereof.

7. Compounds of the formula I of claim 1 , wherein:

R 9 is hydrogen or (C 1 -C 4 ) alkyl;

R 10 is (C 1 -C 4 ) alkyl; and

R 11 is selected from the group consisting of (4-methoxy)phenyl and 2-thienyl.

8. Compounds of the formula I of claim 1 , wherein:

R 9 is hydrogen, methyl, ethyl or tert-butyl;

R 10 is methyl, ethyl or tert-butyl; and

R 11 is selected from the group consisting of (4-methoxy)phenyl and 2-thienyl.

9. Compounds of Formula II:

wherein

R 1 is hydrogen or an amine-protecting group;

R 2 is hydrogen or a carboxyl-protecting group;

wherein at least one of R 1 and R 2 is not hydrogen;

R 3 is selected from the group consisting of H, F, CF 3 , COR 9 , COOR 10 , SOR 10 , SO 2 R 10 , CN and NO 2 ;

R 7 is selected from the group consisting of Y, —O(CH 2 ) n —Y, —(OCH 2 CH 2 ) m —Y, Z,

—OCH 2 —Z; —CH 2 —CH 2 —Z, —CH═CH—Z and —C≡C—Z;

X is selected from CH or N;

Y is selected from 18 F or F;

R 9 is hydrogen or (C 1 -C 6 )alkyl;

R 10 is (C 1 -C 6 )alkyl;

Z is a group

wherein * indicates the atom of connection of Z;

R 5 is selected from the group consisting of H, CF 3 , COR 9 , COOR 10 , SOR 10 ,SO 2 R 10 , CN and NO 2 ;

R 8 is selected from the group consisting of Y, —O(CH 2 ) n —Y and —(OCH 2 CH 2 ) m —Y;

n is 1-3;

and m is 2-3;

with the proviso that if R 7 has the meaning Y, R 3 has the meaning of CF 3 , COR 9 , COOR 10 , SOR 10 , SO 2 R 10 , CN or NO 2 and

with the proviso that if R 8 has the meaning Y, R 5 has the meaning of CF 3 , COR 9 , COOR 10 , SOR 10 , SO 2 R 10 , CN or NO 2 ;

including E and Z-isomers and diastereomers, mixtures thereof, and any pharmaceutically acceptable salt or complex thereof.

10. Compounds according to claim 9 , wherein

R 1 is hydrogen or an amine-protecting group;

R 2 is hydrogen or a carboxyl-protecting group;

wherein at least one of R 1 and R 2 is not hydrogen;

R 3 is H, F, CF 3 , CN or NO 2 ;

R 7 is Y, —O(CH 2 ) n —Y, —(OCH 2 CH 2 ) m —Y, Z, —OCH 2 —Z; —CH 2 —CH 2 —Z, —CH═CH—Z or —C≡C—Z;

X is CH or N;

Y is 18 F or F;

Z is a group

wherein * indicates the atom of connection of Z;

R 5 is H, CF 3 , CN or NO 2 ;

R 8 is Y, —O(CH 2 ) n —Y or —(OCH 2 CH 2 ) m —Y;

n is 1-3;

and m is 2-3;

with the proviso that if R 7 has the meaning of Y, R 3 has the meaning of CF 3 , CN or NO 2 and

with the proviso that if R 8 has the meaning of Y, R 5 has the meaning of CF 3 , CN or NO 2 ;

including E and Z-isomers and diastereomers and mixtures thereof.

11. Compounds according to claim 9 , wherein

R 1 is hydrogen or an amine-protecting group selected from the group consisting of tert-butyloxycarbonyl (BOC), carbobenzyloxy (Cbz) and 9-fluorenylmethyloxycarbonyl (FMOC);

R 2 is hydrogen or a carboxyl-protecting group selected from the group consisting of methyl, ethyl, propyl, tert-butyl, benzyl and p-methoxybenzyl;

wherein at least one of R 1 and R 2 is not hydrogen;

R 3 is H, F, CF 3 , CN or NO 2 ;

R 7 is Y, —O(CH 2 ) n —Y, —(OCH 2 CH 2 ) m —Y, Z, —OCH 2 —Z; —CH 2 —CH 2 —Z, —CH═CH—Z or —C≡C—Z;

X is N;

Y is 18 F or F;

Z is a group

wherein * indicates the atom of connection of Z;

R 5 is H, CF 3 , CN or NO 2 ;

R 8 is Y, —O(CH 2 ) n —Y or —(OCH 2 CH 2 ) m —Y;

n is 1-3;

and m is 2-3;

with the proviso that if R 7 has the meaning of Y, R 3 has the meaning of CF 3 , CN or NO 2 and

with the proviso that if R 8 has the meaning of Y, R 5 has the meaning of CF 3 , CN or NO 2 ;

including E and Z-isomers and diastereomers and mixtures thereof.

12. Compounds according to claim 9 , wherein

R 1 is tert-butyloxycarbonyl (BOC);

R 2 is methyl or tert-butyl;

R 3 is H;

R 7 is —O(CH 2 ) n —Y;

X is N;

Y is 18 F or F;

Z is a group

wherein * indicates the atom of connection of Z;

R 5 is H, CF 3 , CN or NO 2 ;

R 8 is Y, —O(CH 2 ) n —Y or —(OCH 2 CH 2 ) m —Y;

n is 1-3;

and m is 2-3;

with the proviso that if R 8 has the meaning of Y, R 5 has the meaning of CF 3 , CN or NO 2 ;

including E and Z-isomers and diastereomers and mixtures thereof.

13. Compounds of Formula II according to claim 9 , selected from:

3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[3-(2-fluoroethoxy)phenyl]propanoic acid,

3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[4-(2-fluoroethoxy)phenyl]propanoic acid,

tert-butyl 4-{3-[(3R)-3-({(1S)-3-tert-butoxy-1-[5-(2-fluoroethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl-4-{3-[(3R)-3-{[(1S)-1-(3-{2-[2-(2-fluoroethoxy)ethoxy]ethoxy}phenyl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl-4-{3-[(3R)-3-{[(1S)-1-(5-{2-[2-(2-fluoroethoxy)ethoxy]ethoxy}pyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-{[1-{5-[3-(2-fluoroethoxy)phenyl]pyridin-3-yl}-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-{5-[3-(2-fluoroethoxy)phenyl]pyridin-3-yl}propanoic acid,

tert-butyl 4-(3-{(3R)-3-[(1-{5-[4-(2-fluoroethoxy)phenyl]pyridin-3-yl}-3-methoxy-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate,

3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-{5-[4-(2-fluoroethoxy)phenyl]pyridin-3-yl}propanoic acid,

tert-butyl 4-(3-{(3R)-3-[(1-{5-[2-(2-fluoroethoxy)phenyl]pyridin-3yl}-3-methoxy-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate,

3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]-carbonyl}amino)-3-{5-[2-(2-fluoroethoxy)phenyl]pyridin-3-yl}propanoic acid,

tert-butyl 4-{3-[(3R)-3-({1-[5-(3-cyano-4-fluorophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[5-(3-cyano-4-fluorophenyl)pyridin-3-yl]propanoic acid,

tert-butyl 4-{3-[(3R)-3-({1-[5-(4-cyano-3-fluorophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[5-(4-cyano-3-fluorophenyl)pyridin-3-yl]propanoic acid,

tert-butyl 4-{3-[(3R)-3-({1-[5-(4-fluoro-3-nitrophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[5-(4-fluoro-3-nitrophenyl)pyridin-3-yl]propanoic acid,

tert-butyl 4-{3-[(3R)-3-{[(1S)-1-{5-[(3-cyano-4-fluorobenzyl)oxy]pyridin-3-yl}-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-{[(1S)-1-{5-[(4-cyano-3-fluorobenzyl)oxy]pyridin-3-yl}-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[4-(2-fluoroethoxy)phenyl]ethynyl}-pyridine-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[3-(2-fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-({1-[5-fluoro-4′-(2-fluoroethoxy)biphenyl-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[5-fluoro-4′-(2-fluoroethoxy)biphenyl-3-yl]propanoic acid,

tert-butyl 4-{3-[(3R)-3{[(1S)-3-tert-butoxy-1-({[4-(2-fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-({[3-(2-fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

(E/Z) tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-({[3-(2-fluoroethoxy)phenyl]ethenyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-{[(1S)-1-{3-[2-[ 18 F]fluoroethoxy]phenyl}-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(3S)-3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]-carbonyl}amino)-3-{3-[2-[ 8 F]fluoroethoxy]phenyl}propanoic acid,

tert-butyl 4-{3-[(3R)-3-({1-[4-(2-[ 18 F]fluoroethoxy)phenyl]-3-methoxy-3-oxopropyl}-carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-{4-[2-[ 18 F]fluoroethoxy]phenyl}propanoic acid,

tert-butyl 4-{3-[(3R)-3-({(1S)-3-tert-butoxy-1-[5-(2-[ 18 F]fluoroethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-({(1S)-1-[5-(2-[ 18 F]fluoroethoxy)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

(3S)-3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-{5-[2-[ 18 F]fluoroethoxy]pyridin-3-yl}propanoic acid,

tert-butyl 4-(3-{(3R)-3-[(1-{5-[2-[ 18 F]fluoroethoxy]pyridin-3-yl}-3-methoxy-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate,

3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]-carbonyl}amino)-3-{5-[2-[ 18 F]fluoroethoxy]pyridin-3-yl}propanoic acid,

tert-butyl 4-{3-[(3R)-3-{[(1S)-1-(5-{4-[2-[ 18 F]fluoroethoxy]phenyl}pyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

(3S)-3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]-carbonyl}amino)-3-(5-{4-[2-[ 18 F]fluoroethoxy]phenyl}pyridin-3-yl)propanoic acid,

tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{4-[2-[ 18 F]fluoroethoxy]phenyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-(3-{(3R)-3-[(1-{5-[3-cyano-4-[ 18 F]fluorophenyl]pyridin-3-yl}-3-methoxy-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate,

3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[5-(3-cyano-4-[ 18 F]fluorophenyl)pyridin-3-yl]propanoic acid,

tert-butyl 4-(3-{(3R)-3-[(1-{5-[4-cyano-3-[ 18 F]fluorophenyl]pyridin-3-yl}-3-methoxy-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate,

3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-{5-[4-cyano-3-[ 18 F]fluorophenyl]pyridin-3-yl}propanoic acid,

tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[4-(2-[ 18 F]fluoroethoxy)phenyl]ethynyl}pyridine-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[3-(2-[ 18 F]fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-({[4-(2-[ 18 F]fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-({[3-(2-[ 18 F]fluoroethoxy)phenyl]ethyl }pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate,

tert-butyl 4-{3-[(3R)-3-({1-[3-(2-{2-[2-[ 18 F]fluoroethoxy]ethoxy}ethoxy)phenyl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, and

3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[3-(2-{2-[2-[ 18 F]fluoroethoxy]ethoxy}ethoxy)phenyl]propanoic acid.

14. Compounds of the formula II of claim 9 , wherein:

R 9 is hydrogen or (C 1 -C 4 ) alkyl; and

R 10 is (C 1 -C 4 ) alkyl.

15. Compounds of the formula II of claim 9 , wherein:

R 9 is hydrogen, methyl, ethyl or tert-butyl; and

R 10 is methyl, ethyl or tert-butyl.

Assignments (4)
CHANGE OF ADDRESS Recorded Feb 9, 2023
From: LIFE MOLECULAR IMAGING LIMITED
To: LIFE MOLECULAR IMAGING LIMITED
Reel/Frame 064124/0514 →
NUNC PRO TUNC ASSIGNMENT Recorded Mar 11, 2022
From: LIFE MOLECULAR IMAGING SA
To: LIFE MOLECULAR IMAGING LIMITED
Reel/Frame 059861/0901 →
CHANGE OF NAME Recorded May 22, 2019
From: PIRAMAL IMAGING SA
To: LIFE MOLECULAR IMAGING SA
Reel/Frame 049252/0547 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2016
From: BERGER, MARKUS; KRUGER, MARTIN; LOHRKE, JESSICA; SIEBENEICHER, HOLGER; REINHARDT, MICHAEL
To: PIRAMAL IMAGING SA
Reel/Frame 037768/0509 →
Priority Claims (1)
EP 11075195 · Aug 17, 2011 · regional
Continuity (2)
Division 14239065
Related Publication 20160137629A1 · May 19, 2016